This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher (TMO) to Buy Patheon, Expand in Biopharma
by Zacks Equity Research
Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently agreed to acquire Netherlands-based Patheon N.V.
Thermo Fisher (TMO) Tops Q1 Earnings, Sales, Raises Guidance
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected first-quarter 2017 earnings results.
Thermo Fisher (TMO) Beats on Q1 Earnings & Sales Estimates
by Zacks Equity Research
Currently, Thermo Fisher has a Zacks Rank #3 (Hold) but that could change following its promising first-quarter 2017 earnings report which has just released.
Thermo Fisher (TMO) Up 4.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Thermo Fisher (TMO) Pull a Surprise in Q1 Earnings?
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) is scheduled to report first-quarter 2017 results before the opening bell on Apr 26.
Should Value Investors Consider Thermo Fisher (TMO) Stock?
by Zacks Equity Research
Let's see if Thermo Fisher Scientific, Inc. (TMO) stock is a good choice for value-oriented investors right now from multiple angles.
Trump, Biogen and Amgen Hammer Healthcare ETFs
by Sweta Killa
After making a strong comeback in February, the U.S. healthcare sector again witnessed some pain in the last couple of sessions.
Thermo Fisher Poised on Innovation, Global Growth Amid Woes
by Zacks Equity Research
On Mar 17, 2017, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO).
The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines
Top Research Reports for February 1, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), PayPal (PYPL) and Thermo Fisher (TMO).
Thermo Fisher (TMO) Q4 Earnings Beat, Organic Sales Flat
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected fourth-quarter and full-year 2016 earnings results.
Thermo Fisher (TMO): Tops Q4 Earnings, Misses Revenues
by Zacks Equity Research
Thermo Fisher (TMO) has posted earnings which has beaten the Zacks Consensus Estimate but its revenues missed the mark.
4 Stocks with Great Earnings Charts
by Tracey Ryniec
Companies that beat nearly every quarter are earnings all-stars.
Medical Products Stocks' Earnings on Jan 31: ZBH, TMO, ABC
by Zacks Equity Research
Let's take a look at the major Medical Product stocks slated to release their earnings results on tomorrow.
Will Thermo Fisher (TMO) Beat Earnings Estimates in Q4?
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) is scheduled to report fourth-quarter and full-year 2016 results before the opening bell on Jan 31.
Top Research Reports for January 12, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Goldman Sachs (GS), Canadian National Railway (CNI) and Boeing (BA).
5 GARP Stocks that Should Grace Your Portfolio
by Zacks Equity Research
Growth at a reasonable price or GARP is speculated to offer investors a chance to get hold of stocks that are undervalued but have impressive growth potential.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Arch Capital Group, IPG Photonics, AngioDynamics and Express Scripts Holding
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Arch Capital Group, IPG Photonics, AngioDynamics and Express Scripts Holding
Postive Bank Results This Earnings Season
by Sheraz Mian
Plenty of results are still to come, but the big banks are showing a notable improvement in their earnings power.
New Research Reports for Tesla, Exxon, JNJ & Others
by Sheraz Mian
Today's must-read reports are for Exxon Mobil (XOM), Johnson & Johnson (JNJ) and Tesla (TSLA).
Top 7 Research Reports for July 29, 2016
by Sheraz Mian
Today's must-read reports are for Amgen (AMGN), JPMorgan (JPM) and Mondelez (MDLZ).
4 Medical Instrument Stocks to Bet on This Earnings Season
by Zacks Equity Research
The medical instrument sector holds a lot of promise at this moment.
Rush in Medical Device Investments: Should You Buy These Stocks?
by Zacks Equity Research
Coming to the weakest links in the MedTech sector, we advise investors against names that offer little growth/opportunity in the near term.
Should You Buy Evolving Trends in Medical Devices?
by Zacks Equity Research
Given the U.S. government's pushback on tax-dodging, we expected some sloth to creep into the medical device space as far as M&As are concerned. But to our surprise, M&A activity worldwide has remained fairly stable.